| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 14,430 | 8,380 | 2,240 | 3,900 | 4,150 |
| Sales Growth | +72.20% | +274.11% | -42.56% | -6.02% | -61.57% |
| Net Income | -7,710 | -14,180 | -16,530 | -15,880 | -18,200 |
| Net Income Growth | +45.63% | +14.22% | -4.09% | +12.75% | -39.25% |
Omniab Inc (OABI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
OmniAb Inc. discovery platform provides pharmaceutical industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. OmniAb Inc., formerly known as Avista Public Acquisition Corp. II, is based in SAN DIEGO.
Fiscal Year End Date: 12/31